Whitehawk Therapeutics Statistics
Want to see WHWK full AI Analyst Report?
Whitehawk Therapeutics (WHWK) Stock Statistics & Valuation Metrics
Total Valuation
Whitehawk Therapeutics has a market cap or net worth of $181.75M. The enterprise value is $183.48M.
- Market Cap
- $181.75M
- Enterprise Value
- $183.48M
Share Statistics
Whitehawk Therapeutics has 59,008,984 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 59,008,984
- Owned by Insiders
- 25.47%
- Owned by Institutions
- 73.88%
Financial Efficiency
Whitehawk Therapeutics’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -83.93%.
- Return on Equity (ROE)
- -0.15
- Return on Assets (ROA)
- -0.14
- Return on Invested Capital (ROIC)
- -83.93%
- Return on Capital Employed (ROCE)
- -0.84
- Revenue Per Employee
- 223.28K
- Profits Per Employee
- -643.63K
- Employee Count
- 32
- Asset Turnover
- 0.05
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Whitehawk Therapeutics is -2.97. Whitehawk Therapeutics’s PEG ratio is 0.00.
- PE Ratio
- -2.97
- PS Ratio
- 0.00
- PB Ratio
- 1.86
- Price to FCF
- -2.51
- Price to Operating Cash Flow
- -4.13
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Whitehawk Therapeutics had revenue of 7.14M and earned -20.60M in profits. Earnings per share was -0.33.
- Revenue
- 7.14M
- Gross Profit
- 6.38M
- Operating Income
- -114.40M
- Pretax Income
- -20.60M
- Net Income
- -20.60M
- EBITDA
- -20.52M
- Earnings Per Share (EPS)
- -0.33
Cash Flow
In the last 12 months, operating cash flow was -73.64M and capital expenditures -3,000, giving a free cash flow of -73.65M billion.
- Operating Cash Flow
- -73.64M
- Free Cash Flow
- -73.65M
- Free Cash Flow per Share
- -0.78
Dividends & Yields
Whitehawk Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -39.87%
- Earnings Yield
- -27.39%
Stock Price Statistics
- Beta
- 1.20
- 52-Week Price Change
- 45.29%
- 50-Day Moving Average
- 3.68
- 200-Day Moving Average
- 3.87
- Relative Strength Index (RSI)
- 47.73
- Average Volume (3m)
- 340.73K
Important Dates
Whitehawk Therapeutics upcoming earnings date is Mar 18, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 18, 2027
- Ex-Dividend Date
- ―
Financial Position
Whitehawk Therapeutics as a current ratio of 10.26, with Debt / Equity ratio of 0.00%
- Current Ratio
- 10.26
- Quick Ratio
- 10.26
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.83
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Whitehawk Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Whitehawk Therapeutics EV to EBITDA ratio is -1.34, with an EV/FCF ratio of -1.57.
- EV to Sales
- 0.00
- EV to EBITDA
- -1.34
- EV to Free Cash Flow
- -1.57
- EV to Operating Cash Flow
- -1.57
Balance Sheet
Whitehawk Therapeutics has $169.67M in cash and marketable securities with $218.00K in debt, giving a net cash position of $169.45M billion.
- Cash & Marketable Securities
- $169.67M
- Total Debt
- $218.00K
- Net Cash
- $169.45M
- Net Cash Per Share
- $2.87
- Tangible Book Value Per Share
- $1.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Whitehawk Therapeutics is $7.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $7.67
- Price Target Upside
- 136.63% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- -100.00%
- EPS Growth Forecast
- -825.52%
Scores
- Smart Score
- 6
- AI Score
- 46
